Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)

Angelica Barone, Annunziata Lucarelli, Daniela Onofrillo, Federico Verzegnassi, Sonia Bonanomi, Simone Cesaro, Francesca Fioredda, Anna Paola Iori, Saverio Ladogana, Anna Locasciulli, Daniela Longoni, Marina Lanciotti, Alessandra Macaluso, Rosalba Mandaglio, Nicoletta Marra, Baldo Martire, Matteo Maruzzi, Giuseppe Menna, Lucia Dora Notarangelo, Giovanni Palazzi & 11 others Marta Pillon, Ugo Ramenghi, Giovanna Russo, Johanna Svahn, Fabio Timeus, Fabio Tucci, Chiara Cugno, Marco Zecca, Piero Farruggia, Carlo Dufour, Paola Saracco

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Acquired aplastic anemia (AA) is a rare heterogeneous disease characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3/million inhabitants/year, in Europe, but higher in East Asia. Survival in severe aplastic anemia (SAA) has markedly improved in the past 2. decades because of advances in hematopoietic stem cell transplantation, immunosuppressive and biologic drugs, and supportive care. In SAA hematopoietic stem cell transplant (HSCT) from a matched sibling donor (MSD) is the treatment of choice. If a MSD is not available, the options include immunosuppressive therapy (IST) or unrelated donor HSCT. The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary, evidence-based document issued by a group of pediatric hematologists was discussed, modified and approved during a series of "Consensus Conferences" according to procedures previously validated by the AIEOP Board. The guidelines highlight the importance of referring pediatric patients with AA to pediatric centers with long experience in diagnosis, differential diagnosis, management, supportive care and follow-up of AA.

Original languageEnglish
Pages (from-to)40-47
Number of pages8
JournalBlood Cells, Molecules, and Diseases
Volume55
Issue number1
DOIs
Publication statusPublished - 1 Jun 2015
Externally publishedYes

Fingerprint

Aplastic Anemia
Bone Marrow
Guidelines
Pediatrics
Immunosuppressive Agents
Hematopoietic Stem Cells
Siblings
Tissue Donors
Transplants
Unrelated Donors
Aftercare
Pancytopenia
Far East
Hematopoietic Stem Cell Transplantation
Rare Diseases
Consensus
Differential Diagnosis
Delivery of Health Care
Survival
Incidence

Keywords

  • Acquired aplastic anemia
  • Childhood
  • Guidelines

ASJC Scopus subject areas

  • Molecular Medicine
  • Hematology
  • Molecular Biology
  • Cell Biology

Cite this

Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). / Barone, Angelica; Lucarelli, Annunziata; Onofrillo, Daniela; Verzegnassi, Federico; Bonanomi, Sonia; Cesaro, Simone; Fioredda, Francesca; Iori, Anna Paola; Ladogana, Saverio; Locasciulli, Anna; Longoni, Daniela; Lanciotti, Marina; Macaluso, Alessandra; Mandaglio, Rosalba; Marra, Nicoletta; Martire, Baldo; Maruzzi, Matteo; Menna, Giuseppe; Notarangelo, Lucia Dora; Palazzi, Giovanni; Pillon, Marta; Ramenghi, Ugo; Russo, Giovanna; Svahn, Johanna; Timeus, Fabio; Tucci, Fabio; Cugno, Chiara; Zecca, Marco; Farruggia, Piero; Dufour, Carlo; Saracco, Paola.

In: Blood Cells, Molecules, and Diseases, Vol. 55, No. 1, 01.06.2015, p. 40-47.

Research output: Contribution to journalArticle

Barone, A, Lucarelli, A, Onofrillo, D, Verzegnassi, F, Bonanomi, S, Cesaro, S, Fioredda, F, Iori, AP, Ladogana, S, Locasciulli, A, Longoni, D, Lanciotti, M, Macaluso, A, Mandaglio, R, Marra, N, Martire, B, Maruzzi, M, Menna, G, Notarangelo, LD, Palazzi, G, Pillon, M, Ramenghi, U, Russo, G, Svahn, J, Timeus, F, Tucci, F, Cugno, C, Zecca, M, Farruggia, P, Dufour, C & Saracco, P 2015, 'Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)', Blood Cells, Molecules, and Diseases, vol. 55, no. 1, pp. 40-47. https://doi.org/10.1016/j.bcmd.2015.03.007
Barone, Angelica ; Lucarelli, Annunziata ; Onofrillo, Daniela ; Verzegnassi, Federico ; Bonanomi, Sonia ; Cesaro, Simone ; Fioredda, Francesca ; Iori, Anna Paola ; Ladogana, Saverio ; Locasciulli, Anna ; Longoni, Daniela ; Lanciotti, Marina ; Macaluso, Alessandra ; Mandaglio, Rosalba ; Marra, Nicoletta ; Martire, Baldo ; Maruzzi, Matteo ; Menna, Giuseppe ; Notarangelo, Lucia Dora ; Palazzi, Giovanni ; Pillon, Marta ; Ramenghi, Ugo ; Russo, Giovanna ; Svahn, Johanna ; Timeus, Fabio ; Tucci, Fabio ; Cugno, Chiara ; Zecca, Marco ; Farruggia, Piero ; Dufour, Carlo ; Saracco, Paola. / Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). In: Blood Cells, Molecules, and Diseases. 2015 ; Vol. 55, No. 1. pp. 40-47.
@article{4c77d2d10139439eb28981875bdc9c98,
title = "Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)",
abstract = "Acquired aplastic anemia (AA) is a rare heterogeneous disease characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3/million inhabitants/year, in Europe, but higher in East Asia. Survival in severe aplastic anemia (SAA) has markedly improved in the past 2. decades because of advances in hematopoietic stem cell transplantation, immunosuppressive and biologic drugs, and supportive care. In SAA hematopoietic stem cell transplant (HSCT) from a matched sibling donor (MSD) is the treatment of choice. If a MSD is not available, the options include immunosuppressive therapy (IST) or unrelated donor HSCT. The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary, evidence-based document issued by a group of pediatric hematologists was discussed, modified and approved during a series of {"}Consensus Conferences{"} according to procedures previously validated by the AIEOP Board. The guidelines highlight the importance of referring pediatric patients with AA to pediatric centers with long experience in diagnosis, differential diagnosis, management, supportive care and follow-up of AA.",
keywords = "Acquired aplastic anemia, Childhood, Guidelines",
author = "Angelica Barone and Annunziata Lucarelli and Daniela Onofrillo and Federico Verzegnassi and Sonia Bonanomi and Simone Cesaro and Francesca Fioredda and Iori, {Anna Paola} and Saverio Ladogana and Anna Locasciulli and Daniela Longoni and Marina Lanciotti and Alessandra Macaluso and Rosalba Mandaglio and Nicoletta Marra and Baldo Martire and Matteo Maruzzi and Giuseppe Menna and Notarangelo, {Lucia Dora} and Giovanni Palazzi and Marta Pillon and Ugo Ramenghi and Giovanna Russo and Johanna Svahn and Fabio Timeus and Fabio Tucci and Chiara Cugno and Marco Zecca and Piero Farruggia and Carlo Dufour and Paola Saracco",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.bcmd.2015.03.007",
language = "English",
volume = "55",
pages = "40--47",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)

AU - Barone, Angelica

AU - Lucarelli, Annunziata

AU - Onofrillo, Daniela

AU - Verzegnassi, Federico

AU - Bonanomi, Sonia

AU - Cesaro, Simone

AU - Fioredda, Francesca

AU - Iori, Anna Paola

AU - Ladogana, Saverio

AU - Locasciulli, Anna

AU - Longoni, Daniela

AU - Lanciotti, Marina

AU - Macaluso, Alessandra

AU - Mandaglio, Rosalba

AU - Marra, Nicoletta

AU - Martire, Baldo

AU - Maruzzi, Matteo

AU - Menna, Giuseppe

AU - Notarangelo, Lucia Dora

AU - Palazzi, Giovanni

AU - Pillon, Marta

AU - Ramenghi, Ugo

AU - Russo, Giovanna

AU - Svahn, Johanna

AU - Timeus, Fabio

AU - Tucci, Fabio

AU - Cugno, Chiara

AU - Zecca, Marco

AU - Farruggia, Piero

AU - Dufour, Carlo

AU - Saracco, Paola

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Acquired aplastic anemia (AA) is a rare heterogeneous disease characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3/million inhabitants/year, in Europe, but higher in East Asia. Survival in severe aplastic anemia (SAA) has markedly improved in the past 2. decades because of advances in hematopoietic stem cell transplantation, immunosuppressive and biologic drugs, and supportive care. In SAA hematopoietic stem cell transplant (HSCT) from a matched sibling donor (MSD) is the treatment of choice. If a MSD is not available, the options include immunosuppressive therapy (IST) or unrelated donor HSCT. The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary, evidence-based document issued by a group of pediatric hematologists was discussed, modified and approved during a series of "Consensus Conferences" according to procedures previously validated by the AIEOP Board. The guidelines highlight the importance of referring pediatric patients with AA to pediatric centers with long experience in diagnosis, differential diagnosis, management, supportive care and follow-up of AA.

AB - Acquired aplastic anemia (AA) is a rare heterogeneous disease characterized by pancytopenia and hypoplastic bone marrow. The incidence is 2-3/million inhabitants/year, in Europe, but higher in East Asia. Survival in severe aplastic anemia (SAA) has markedly improved in the past 2. decades because of advances in hematopoietic stem cell transplantation, immunosuppressive and biologic drugs, and supportive care. In SAA hematopoietic stem cell transplant (HSCT) from a matched sibling donor (MSD) is the treatment of choice. If a MSD is not available, the options include immunosuppressive therapy (IST) or unrelated donor HSCT. The objective of this guideline is to provide healthcare professionals with clear guidance on the diagnosis and management of pediatric patients with AA. A preliminary, evidence-based document issued by a group of pediatric hematologists was discussed, modified and approved during a series of "Consensus Conferences" according to procedures previously validated by the AIEOP Board. The guidelines highlight the importance of referring pediatric patients with AA to pediatric centers with long experience in diagnosis, differential diagnosis, management, supportive care and follow-up of AA.

KW - Acquired aplastic anemia

KW - Childhood

KW - Guidelines

UR - http://www.scopus.com/inward/record.url?scp=84929223977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929223977&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2015.03.007

DO - 10.1016/j.bcmd.2015.03.007

M3 - Article

VL - 55

SP - 40

EP - 47

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 1

ER -